Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

1.

Pharmacologically, are smokers the same as non-smokers?

Bani M, Andorn A, Heidbreder C.

Curr Opin Pharmacol. 2014 Feb;14:42-9. doi: 10.1016/j.coph.2013.11.003. Review.

PMID:
24565011
2.

Occupancy of brain dopamine D3 receptors and drug craving: a translational approach.

Mugnaini M, Iavarone L, Cavallini P, Griffante C, Oliosi B, Savoia C, Beaver J, Rabiner EA, Micheli F, Heidbreder C, Andorn A, Merlo Pich E, Bani M.

Neuropsychopharmacology. 2013 Jan;38(2):302-12. doi: 10.1038/npp.2012.171.

3.

Pharmacokinetics and central nervous system effects of the novel dopamine D3 receptor antagonist GSK598809 and intravenous alcohol infusion at pseudo-steady state.

te Beek ET, Zoethout RW, Bani MS, Andorn A, Iavarone L, Klaassen ES, Fina P, van Gerven JM.

J Psychopharmacol. 2012 Feb;26(2):303-14. doi: 10.1177/0269881111431750.

PMID:
22219221
4.

Localized hippocampus measures are associated with Alzheimer pathology and cognition independent of total hippocampal volume.

Carmichael O, Xie J, Fletcher E, Singh B, DeCarli C; Alzheimer's Disease Neuroimaging Initiative..

Neurobiol Aging. 2012 Jun;33(6):1124.e31-41. doi: 10.1016/j.neurobiolaging.2011.08.016.

5.

Using CSF biomarkers to replicate genetic associations in Alzheimer's disease.

Schott JM; ADNI Investigators..

Neurobiol Aging. 2012 Jul;33(7):1486.e9-15. doi: 10.1016/j.neurobiolaging.2011.02.008.

6.

Bupropion has no effect on intraocular pressure or other ophthalmologic parameters after single or repeat doses in healthy volunteers.

Ghibellini G, Park J, Brittain CF, Iavarone L, Andorn AC, Levy N, Muir KT.

J Clin Pharmacol. 2009 Apr;49(4):489-95. doi: 10.1177/0091270008330981. No abstract available.

PMID:
19318697
7.

Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression.

Shelton RC, Andorn AC, Mallinckrodt CH, Wohlreich MM, Raskin J, Watkin JG, Detke MJ.

Int Clin Psychopharmacol. 2007 Nov;22(6):348-55.

PMID:
17917553
8.

Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range.

Mallinckrodt CH, Prakash A, Andorn AC, Watkin JG, Wohlreich MM.

J Psychiatr Res. 2006 Jun;40(4):337-48.

PMID:
16271726
9.
11.

Increased Expression but Reduced Activity of Antioxidant Enzymes in Alzheimer's Disease.

Omar RA, Chyan YJ, Andorn AC, Poeggeler B, Robakis NK, Pappolla MA.

J Alzheimers Dis. 1999 Oct;1(3):139-145.

PMID:
12213999
12.

Catecholamines inhibit lipid peroxidation in young, aged, and Alzheimer's disease brain.

Andorn AC, Pappolla MA.

Free Radic Biol Med. 2001 Aug 1;31(3):315-20.

PMID:
11461768
13.

Ascorbate-stimulated lipid peroxidation and non-heme iron concentrations in Alzheimer disease.

Andorn AC, Britton RS, Bacon BR, Kalaria RN.

Mol Chem Neuropathol. 1998 Jan;33(1):15-26.

PMID:
9493173
14.

Ascorbate-stimulated lipid peroxidation in human brain is dependent on iron but not on hydroxyl radical.

Andorn AC, Britton RS, Bacon BR.

J Neurochem. 1996 Aug;67(2):717-22.

PMID:
8764600
16.

Binding of [3H]-p-aminoclonidine to alpha 2-adrenoceptor states plus a non-adrenergic site on human platelet plasma membranes.

Piletz JE, Andorn AC, Unnerstall JR, Halaris A.

Biochem Pharmacol. 1991 Jul 15;42(3):569-84.

PMID:
1677571
18.

Adrenergic receptors in aging and Alzheimer's disease: increased beta 2-receptors in prefrontal cortex and hippocampus.

Kalaria RN, Andorn AC, Tabaton M, Whitehouse PJ, Harik SI, Unnerstall JR.

J Neurochem. 1989 Dec;53(6):1772-81.

PMID:
2553864
19.

Concurrent neuroborreliosis and Alzheimer's disease: analysis of the evidence.

Pappolla MA, Omar R, Saran B, Andorn A, Suarez M, Pavia C, Weinstein A, Shank D, Davis K, Burgdorfer W.

Hum Pathol. 1989 Aug;20(8):753-7.

PMID:
2744748
20.

Supplemental Content

Loading ...
Support Center